Neoplasia · 2014 · 36 citations · 41 references
MedicineGeneticsMolecular GeneticsCancer GeneticsEpigeneticsMolecular OncologyCancer EpigeneticsEpigenetic Alterations In CancerEpigenetic Regulation In CancerMolecular CytogeneticsMutation AnalysisOncogene MutationsAcute LeukemiasAcute Myeloid Leukemia BiologyGene Mutation DetectionLeukemia ClassificationLeukemia CytogeneticsMutationMutational Spectrum AnalysisRunx1 In Hematopoietic Development
Minimally differentiated acute myeloid leukemia (AML-M0) is a rare subtype of AML with poor prognosis. Although genetic alterations are increasingly reported in AML, the gene mutations have not been comprehensively studied in AML-M0. We aimed to examine a wide spectrum of gene mutations in patients with AML-M0 to determine their clinical relevance. Twenty gene mutations including class I, class II, class III of epigenetic regulators (IDH1, IDH2, TET2, DNMT3A, MLL-PTD, ASXL1, and EZH2), and class IV (tumor suppressor genes) were analyzed in 67 patients with AML-M0. Mutational analysis was performed with polymerase chain reaction-based assays followed by direct sequencing. The most frequent gene mutations from our data were FLT3-ITD/FLT3-TKD (28.4%), followed by mutations in IDH1/IDH2 (28.8%), RUNX1 (23.9%), N-RAS/K-RAS (12.3%), TET2 (8.2%), DNMT3A (8.1%), MLL-PTD (7.8%), and ASXL1 (6.3%). Seventy-nine percent (53/67) of patients had at least one gene mutation. Class I genes (49.3%) were the most common mutated genes, which were mutually exclusive. Class III genes of epigenetic regulators were also frequent (43.9%). In multivariate analysis, old age [hazard ratio (HR) 1.029, 95% confidence interval (CI) 1.013-1.044, P=.001) was the independent adverse factor for overall survival, and RUNX1 mutation (HR 2.326, 95% CI 0.978-5.533, P=.056) had a trend toward inferior survival. In conclusion, our study showed a high frequency of FLT3, RUNX1, and IDH mutations in AML-M0, suggesting that these mutations played a role in the pathogenesis and served as potential therapeutic targets in this rare and unfavorable subtype of AML.
41
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
E. Joanna Baxter, Linda M. Scott, Peter J. Campbell et al. · The Lancet · 2005 · 3.4K citations
Life Sciences, Genetics, Hematology +14
<i>DNMT3A</i> Mutations in Acute Myeloid Leukemia
Timothy J. Ley, Li Ding, Matthew J. Walter et al. · New England Journal of Medicine · 2010 · 2K citations · Full text
Panagiotis Kottaridis, Rosemary E. Gale, Marion E. Frew et al. · Blood · 2001 · 1.5K citations · Full text
Life Sciences, Genetics, Hematology +16
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
E. Joanna Baxter, Linda M. Scott, Peter J. Campbell et al. · The Lancet · 2005 · 1.1K citations
Life Sciences, Genetics, Hematology +14